Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields - B

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Pfizer Inc. (NYSE:PFE)

Dividend Yield: 5.38%
Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $39 to $37 on Nov. 1, 2023. This analyst has an accuracy rate of 66%.
Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $39 to $35 on Oct. 17, 2023. This analyst has an accuracy rate of 71%.
Recent News: Astellas Pharma and Pfizer announced FDA approval of supplemental marketing application for Xtandi (Enzalutamide) for nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Bristol-Myers Squibb Company (NYSE:BMY)

Dividend Yield: 4.58%
BMO Capital analyst Evan Seigerman downgraded the stock from Outperform to Market Perform with a price target of $60. This analysts has an accuracy rate of 61%.
HSBC analyst Rajesh Kumar upgraded the stock from Reduce to Hold and lowered the price target from $55 to $53 on Oct. 27, 2023.This analyst has an accuracy rate of 61%.
Recent News: The FDA approved Bristol Myers Squibb’s Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Premier, Inc. (NASDAQ:PINC)

Dividend Yield: 4.02%
JP Morgan analyst Anne Samuel maintained a Neutral rating and cut the price target from $26 to $21 on Nov. 13, 2023. This analyst has an accuracy rate of 63%.
UBS analyst Kevin Caliendo maintained a Neutral rating and cut the price target from $29 to $26 on Aug. 23, 2023. This analyst has an accuracy rate of 78%.
Recent News: Premier posted upbeat earnings for the first quarter.

BMYBristol-Myers Squibb Co

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.